+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD222 mouse mAb (green) and negative control (red).    

  
  

CD222 antibody targets the CD222 antigen, also known as the insulin-like growth factor 2 receptor (IGF2R). CD222 is a transmembrane glycoprotein primarily involved in intracellular trafficking, lysosomal enzyme sorting, and regulation of insulin-like growth factor 2 (IGF2) signaling. It functions as a scavenger receptor by binding and internalizing IGF2. a critical mitogen, thereby modulating cell growth and differentiation. CD222 also participates in the activation of transforming growth factor-beta (TGF-β) through interaction with latent complexes.

CD222 is ubiquitously expressed in various tissues, with roles in embryogenesis, tumor suppression, and metabolic regulation. Dysregulation of CD222 has been linked to cancers, neurodegenerative disorders, and developmental abnormalities. For instance, loss-of-function mutations in CD222 are associated with increased IGF2 bioavailability, promoting tumor growth. Conversely, overexpression in some cancers highlights its dual context-dependent roles.

CD222 antibodies are valuable tools in research and diagnostics. They enable detection of CD222 expression in tissues or cell lines, aiding studies on receptor localization, trafficking, and IGF2-related pathways. Therapeutic applications are under exploration, particularly in oncology, where antibody-drug conjugates (ADCs) or bispecific antibodies targeting CD222 aim to deliver cytotoxic agents or enhance immune responses. Challenges remain in ensuring antibody specificity and minimizing off-target effects due to CD222's structural complexity and widespread expression. Ongoing research focuses on optimizing CD222-targeted therapies and clarifying its mechanistic roles in disease.